AskBio's recent news on a gene therapy for Parkinson's disease is mostly a story about delivery. The candidate, AB-1005, is an investigational gene therapy for moderate Parkinson's disease, and it has received FDA Fast Track and UK MHRA Innovation Passport designations. The mechanism behind that progress is convection-enhanced delivery (CED), which places the vector directly into a defined brain region.
The same requirement runs through CNS (central nervous system) research whenever a program depends on local exposure. Prisys Biotech, a preclinical CRO, runs an intraprocedural MRI (iMRI) brain injection system and CED work in cynomolgus monkeys, which is the combination that turns a delivery plan into a measured procedure.
MRI-Compatible Brain Injection System
Prisys Biotech's intraprocedural MRI (iMRI) brain injection system images the brain while the injection is running. Real-time imaging allows precise targeting of specific brain regions, and it confirms that the cannula sits where the plan placed it.
Keeping the target in view through the procedure reduces the risk of off-target effects. Continuous monitoring during the injection covers the subject's safety and lets the operator stop if the infusate spreads outside the planned volume. Accurate delivery is also what makes the injected agent assessable, so precision and safety sit upstream of any efficacy readout.
For a preclinical study, the practical effect is that delivery becomes a measured variable. Coverage in each animal is recorded with the injection, so an efficacy result can be read against what actually reached the target.
Convection-Enhanced Delivery (CED) Technology
Convection-enhanced delivery (CED) technology infuses a therapeutic agent directly into a specific brain region under continuous positive pressure. The pressure gradient carries the infusate through the extracellular space beyond the catheter tip, and that is what separates it from a bolus that spreads mainly by diffusion.
The result is a more homogeneous distribution of the agent within the target area, lower systemic exposure because the drug stays in the intended region, and deeper penetration than passive diffusion allows. That last point decides the outcome for large molecules. Proteins, viral vectors, and other macromolecules move poorly through brain tissue on their own, so a method that depends on diffusion leaves most of the target untreated.
CED is used for gene therapies, proteins, and other macromolecules that need precise localization within the brain. It is one form of Intracerebral (ICM) Injection, with controlled pressure and a defined infusion time in place of a single bolus. Where the target is the ventricular space, Intracerebroventricular (ICV) Injection reaches it through the CSF instead, trading parenchymal coverage for a larger distribution volume.
Preclinical Research Services with Cynomolgus Monkeys
Prisys Biotech offers preclinical research services in cynomolgus monkeys, a model used for CNS work because the physiological and anatomical similarity to humans is close. The services sit within the company's NHP Pharmacology work and cover three areas.
Pharmacokinetics (PK) and Pharmacodynamics (PD) studies assess how a therapeutic agent distributes within the CNS and what effect it produces there. For a locally delivered agent, the concentration that matters is in the target structure and in the CSF, and both can be sampled over time.
Efficacy studies evaluate the therapeutic potential of a new treatment in a disease model that reproduces the relevant phenotype, with delivery performed the way it would be in the clinic.
Safety and toxicology studies establish that a new CNS therapy is safe before clinical trials. With direct delivery, that includes the tissue response to the procedure itself, which is a separate question from systemic toxicity and one that only a delivery study can answer.
An iMRI system and CED technology, combined with experience in cynomolgus monkeys, are what let a CNS program separate a drug effect from a delivery effect. Prisys Biotech provides that work for sponsors developing treatments for neurological disorders, and the images and coverage data it produces are the part of a preclinical package that a clinical protocol can be built on.
